Ingo Stock
Impact in
- Molecular Medicine top 1%
- Antibiotic Resistance in Bacteria
- Endocrinology top 1%
- Enterobacteriaceae and Cronobacter Research
- Vibrio bacteria research studies
Papers in
-
- Antibiotic Resistance in Bacteria 21
-
- Enterobacteriaceae and Cronobacter Research 9
- Co-authors
- B. WiedemannGuido FunkeRobert F. TroxlerAlexander von GraevenitzPeter HeisigMotiur RahmanAndrea SchieferIrith Wiegand
- Journals
- Diagnostic Microbiology and Infectious Disease (5 papers)Journal of Medical Microbiology (5 papers)Journal of Chemotherapy (4 papers)International Journal of Antimicrobial Agents (4 papers)Clinical Microbiology and Infection (3 papers)
- Partner nations
- GermanySwitzerlandSweden
In The Last Decade
Ingo Stock
58 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 98
- Molecular Medicine 461
- Endocrinology 465
- Biotechnology 207
- Applied Microbiology and Biotechnology 41
- Clinical Biochemistry 114
Countries citing papers authored by Ingo Stock
This map shows the geographic impact of Ingo Stock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingo Stock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingo Stock more than expected).
Fields of papers citing papers by Ingo Stock
This network shows the impact of papers produced by Ingo Stock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingo Stock. The network helps show where Ingo Stock may publish in the future.
Co-authors
The 8 scholars most cited alongside Ingo Stock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Syphilis – an update. | 2017 | 2 |
| 2 | [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria]. | 2015 | 2 |
| 3 | [Infections with Chlamydia trachomatis]. | 2012 | 6 |
| 4 | 2005 | 12 | |
| 5 | 2005 | 12 | |
| 6 | 2004 | 65 | |
| 7 | 2004 | 26 | |
| 8 | 2003 | 20 | |
| 9 | 2003 | 8 | |
| 10 | 2003 | 59 | |
| 11 | 2003 | 84 | |
| 12 | 2003 | 101 | |
| 13 | 2003 | 13 | |
| 14 | 2002 | 79 | |
| 15 | 2002 | 5 | |
| 16 | 2001 | 40 | |
| 17 | 2001 | 24 | |
| 18 | 2000 | 164 | |
| 19 | 1999 | 42 | |
| 20 | 1998 | 64 |
About Ingo Stock
Ingo Stock is a scholar working on Molecular Medicine, Endocrinology, Applied Microbiology and Biotechnology, Pharmacology and Infectious Diseases, having authored 61 papers that have together received 1.4k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (21 papers), Enterobacteriaceae and Cronobacter Research (9 papers), Yersinia bacterium, plague, ectoparasites research (7 papers), Pharmacological Effects of Natural Compounds (5 papers), Plant-based Medicinal Research (5 papers), Nail Diseases and Treatments (4 papers), Respiratory viral infections research (4 papers) and Mosquito-borne diseases and control (4 papers). The work is most often cited by research in Molecular Medicine (461 citations), Endocrinology (465 citations), Biotechnology (207 citations), Applied Microbiology and Biotechnology (41 citations) and Clinical Biochemistry (114 citations). Ingo Stock has collaborated with scholars based in Germany, Switzerland and Sweden. Frequent co-authors include B. Wiedemann, Guido Funke, Robert F. Troxler, Alexander von Graevenitz, Peter Heisig, Motiur Rahman, Andrea Schiefer and Irith Wiegand. Their work appears in journals such as Diagnostic Microbiology and Infectious Disease, Journal of Medical Microbiology, Journal of Chemotherapy, International Journal of Antimicrobial Agents and Clinical Microbiology and Infection.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.